ArticlePituitary2026
Adverse hepato-biliary-pancreatic events in acromegaly patients treated with first generation somatostatin receptor ligands.
Article in Pituitary, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
First-generation somatostatin receptor ligands (SRLs) are first-line medical therapy for acromegaly. During long-term treatment, hepato-biliary-pancreatic adverse events can occur. This study aimed to evaluate the prevalence and predictors of hepato-biliary-pancreatic adverse events during SRL-treatment.In this multicenter study, data of 371 acromegaly patients (223 females) were retrospectively collected at the start of SRL therapy (T0), and at the last follow-up visit (120 ± 97.31 months). The occurrence of hepato-biliary-pancreatic adverse events and their relationship with features at T0 were investigated.Sixty-one patients (16.4%) underwent cholecystectomy (CH-Tx), cholecystitis (CH) occurred in 3.8%, severe or mild hyperlipasemia/hyperamylasemia in 2.2% and in 5.1%, severe or mild hypertransaminasemia in 1.1% and in 6.4%,respectively. No significant differences emerged after patient stratification by gender or age (≤/>50yrs). BMI, GH and IGF1 values were not associated with a higher risk of biliary complications. Patients undergoing CH-Tx or CH had a higher prevalence of cholelithiasis at T0 (p = 0.002 and p = 0.005). Cholelithiasis (p = 0.040) and biliary sludge (p = 0.014) at T0 were independent predictors of cholecystectomy. Cholelithiasis also strongly predicted cholecystitis in both univariable (p = 0.012) and multivariable (p = 0.025) analyses. Ursodeoxycholic acid (UDCA) treatment was associated with cholecystitis (p = 0.007) and mild-hypertransaminasemia (p = 0.035). When considering overall hepato-biliary-pancreatic adverse events, cholelithiasis, biliary sludge and age at T0 were significant predictors in both univariate (p = 0.006,p = 0.010,p = 0.013) and multivariable analysis (p = 0.029,p = 0.028,p = 0.044).Hepato-biliary-pancreatic adverse events are not infrequent during long-term SRLs therapy and are influenced overall by older age, cholelithiasis and biliary sludge.
Indexed as
Identifiers
41934517What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.